Canakinumab is a Monoclonal Antibody owned by Novartis, and is involved in 83 clinical trials, of which 63 were completed, 19 are ongoing, and 1 is planned.
Canakinumab is a fully human monoclonal anti-human interleukin-1beta (IL-1 Beta) antibody of the IgG1/k isotype. Canakinumab binds with high affinity specifically to human IL-1 beta and neutralizes its activity by blocking its interaction with IL-1 beta receptors, and thereby, prevents IL-1 1beta -induced gene activation and the production of inflammatory mediators, such as interleukin-6 or cyclooxygenase-2.
The revenue for Canakinumab is expected to reach a total of $13.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Canakinumab NPV Report.
Canakinumab is originated and owned by Novartis.
Canakinumab (Ilaris / Lasprona / Vyncro) is a fully human monoclonal antibody. It is formulated as powder for solution and solution for subcutaneous route of administration. Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including Familial Cold Autoinflammatory Syndrome (FCAS), tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), Familial Mediterranean Fever (FMF), Muckle-Wells Syndrome (MWS), pancreatic cancer and symptomatic anemia. Ilaris is also approved for systemic onset juvenile idiopathic arthritis in patients aged 2 years and older. Ilaris is also indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks, and for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Canakinumab is indicated for emergency use in the treatment of COVID-19.
Canakinumab (Ilaris) is under development for the treatment of myelodysplastic syndromes, mild cognitive impairment due to Alzheimer's disease, adult onset still's disease (AOSD), renal cell carcinoma, metastatic non-squamous (adjuvant and first line therapy), metastatic triple negative breast cancer, pulmonary sarcoidosis, metastatic melanoma, alcoholic hepatitis and pain associated with sickle cell anemia patients. It was under development for the treatment of arterial structure, function in intermittent claudication patients, gouty arthritis (in the US), abdominal aortic aneurysms, choroidal neovascularization, rheumatoid arthritis, type 1 diabetes, type 2 diabetes, chronic obstructive pulmonary disease (COPD), feratoconjunctivitis sicca (dry eye), secondary prevention of cardiovascular events, Kawasaki disease, urticaria vasculitis, polymyalgia rheumatica, non-small cell lung cancer (second line and third line therapy) and knee osteoarthritis. It is also administered through intraarticular route. It was also under development for the treatment of COVID-19-induced pneumonia, cytokine release syndrome and squamous non-small cell lung cancer (first line therapy), Behcet disease.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.
Quick View – Canakinumab
|Highest Development Stage|